Roche【1RO】銘柄情報

Roche Holding AG (1RO) 銘柄情報

リアルタイムのディスカッションと取引のアイデア: 当社の強力なプラットフォームで自信を持って取引できます。

プレミアム

通貨

362.80

( -0.87% )

買値

183.00

売値

549.00

出来高

362.40 日の範囲 362.80

270.00 52 週間の範囲 422.00

時価総額

288.65B

前日終値

366.00

始値

362.40

時刻

362.8

最終取引時間

財務取引量

VWAP

平均取引量 (3 か月)

1,020,677 €

発行済株式数

795,617,637

配当利回り

9.8 (3.11%)

PER

19.31

1 株当たり利益 (EPS)

16.04

歳入

63.36B

純利益

12.88B

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases... Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and others; diagnostic instruments; and digital health solutions. The company was founded in 1896 and is based in Basel, Switzerland. 詳細を表示

セクター

業界

ウェブサイト

www.roche.com

本社

Basel, Switzerland

設立

1896

Roche Holding AG is listed in the sector of the イタリア証券取引所 with ticker 1RO. The last closing price for Roche was 366.00 €. Over the last year, Roche shares have traded in a share price range of 270.00 € to 422.00 €.

Roche currently has 795,617,637 shares in issue. The market capitalisation of Roche is 288.65 € billion. Roche has a price to earnings ratio (PE ratio) of 19.31.

FDA accepts New Drug Application for Roche’s giredestrant in ER-positive early-stage breast cancer, the first and only oral SERD with positive phase III results in the curative setting

FDA accepts New Drug Application for Roche’s giredestrant in ER-positive early-stage breast cancer, the first and only oral SERD with positive...

Roche to present new data advancing its obesity portfolio at the American Diabetes Association’s 2026 Scientific Sessions

Roche to present new data advancing its obesity portfolio at the American Diabetes Association’s 2026 Scientific Sessions Late-breaking Phase II...

Roche launches the Liver Disease Panel, the first suite of certified algorithms to support Chronic Liver Disease management

Roche launches the Liver Disease Panel, the first suite of certified algorithms to support Chronic Liver Disease management Roche introduces the...

Roche to present new data at ASCO 2026, reinforcing giredestrant's potential to transform the treatment paradigm in early breast cancer

Roche to present new data at ASCO 2026, reinforcing giredestrant's potential to transform the treatment paradigm in early breast cancer New...

Roche receives CE mark for new blood test to detect Alzheimer's pathology: Elecsys® plasma phosphorylated-tau 217 (pTau217)

Roche receives CE mark for new blood test to detect Alzheimer's pathology: Elecsys® plasma phosphorylated-tau 217 (pTau217) Elecsys® pTau217...

Roche enters into a definitive merger agreement to acquire PathAI to transform AI-driven diagnostics

Roche enters into a definitive merger agreement to acquire PathAI to transform AI-driven diagnostics PathAI’s best-in-class Image Management...

Roche to present extensive data showcasing its industry-leading ophthalmology portfolio at ARVO 2026

Roche to present extensive data showcasing its industry-leading ophthalmology portfolio at ARVO 2026 New real-world data confirm Vabysmo’s potent...

[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong sales growth of +6% at constant exchange rates in the first quarter of 2026; -5% in CHF due to the significant appreciation of the Swiss franc

[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong sales growth of +6% at constant exchange rates in the first quarter of 2026; -5...

[Ad-hoc-Mitteilung gemäss Art. 53 KR] Starkes Verkaufswachstum der Roche-Gruppe von +6% zu konstanten Wechselkursen im ersten Quartal 2026; -5% in CHF aufgrund der deutlichen Aufwertung des Schweizer Frankens

[Ad-hoc-Mitteilung gemäss Art. 53 KR] Starkes Verkaufswachstum der Roche-Gruppe von +6% zu konstanten Wechselkursen im ersten Quartal 2026; -5% in...

Roche’s fenebrutinib significantly reduced relapses versus standard of care to approximately one every 17 years in RMS

Roche’s fenebrutinib significantly reduced relapses versus standard of care to approximately one every 17 years in RMS Late-breaking Phase III...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	-5.4	-1.46659424226	368.2	368.2	341.6	40	346.48643216	DE
4	9	2.54381006218	353.8	377	341.6	39	358.83964194	DE
12	-1.2	-0.32967032967	364	377.8	338	23	357.21908517	DE
26	16.8	4.85549132948	346	422	334	18	366.85802651	DE
52	52.8	17.0322580645	310	422	270	13	350.78791396	DE
156	56.8	18.5620915033	306	422	270	12	350.07265993	DE
260	56.8	18.5620915033	306	422	270	12	350.07265993	DE